WHO ICTRP trial
A Placebo-Controlled, Double-Blind, Phase II Physician-Initiated Trial of TM5614…
JPRN-jRCT2021210006 · Japan Primary Registries Network (JPRN) · Not Recruiting
Key facts
| Trial ID | JPRN-jRCT2021210006 |
|---|---|
| Public title | A Placebo-Controlled, Double-Blind, Phase II Physician-Initiated Trial of TM5614 in Patients with SARS-CoV-2 Pneumonia |
| Scientific title | A Placebo-Controlled, Double-Blind, Phase II Physician-Initiated Trial of TM5614, a PAI-1 Inhibitor, for the Treatment of SARS-CoV-2 Pneumonia |
| Primary sponsor | Harigae Hideo |
| Registry | Japan Primary Registries Network (JPRN) |
| Recruitment status | Not Recruiting |
| Study type | Interventional |
| Phase | 2 |
| Conditions | novel coronavirus (SARS-CoV-2) pneumonia novel coronavirus pneumonia, novel coronavirus infection;novel coronavirus pneumonia, novel coronavirus infection |
| Interventions | Two tablets of TM5614 (120 mg) or placebo will be administered once daily, and the dose may be increased to 3 tablets at the physician's discretion. However, on Day 7, if bleeding symptoms or hepatic dysfunction are observed, or if… |
| Registration date | May 28, 2021 |
| Target size | 100 |
| Registry page | jrct.niph.go.jp |
At a glance
- No Results available
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About WHO ICTRP trial registrations
The WHO ICTRP combines trial registrations from primary registries worldwide into a single searchable index. Contact and ethics-committee details are not shown here.
Source: World Health Organization (WHO), International Clinical Trials Registry Platform (ICTRP) · Source date: